Lecanemab (brand name Leqembi) is the second monoclonal antibody approved for Alzheimer’s that targets a biological component of the disease rather than Alzheimer’s-associated symptoms, such as agitation. The approval of the other monoclonal antibody called aducanumab (Aduhelm) in 2021 was met with some controversy. Both medications attach to amyloid proteins in the brain and prevent the formation of amyloid plaques, which are associated with Alzheimer’s.
